- Management of Chronic Hepatitis B in Treatment-Naive Patients
-
Cheong JY
- KMID: 1767538
- Korean J Gastroenterol.
- 2008 Jun;51(6):338-345.
Chronic hepatitis B (CHB) is a serious health problem in Korea. The natural history of chronic HBV infection has been divided into 4 phases: immune tolerance, immune clearance, inactive HBsAg... -
- CITED
-
- Close
- SHARE
-
- Close
- Review: Clinical Outcome after Living Donor Liver Transplantation in Patients with Hepatitis C Virus-associated Cirrhosis
-
Kim HJ
- KMID: 1776824
- Korean J Hepatol.
- 2007 Dec;13(4):489-494.
- doi: 10.3350/kjhep.2007.13.4.489
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment of chronic hepatitis B in children with prednisolone withdrawal followed by recombinant interferon alpha
-
Kim HS, Kim JW, Chung KS
- KMID: 711563
- Yonsei Med J.
- 1998 Aug;39(4):309-316.
- doi: 10.3349/ymj.1998.39.4.309
Steroid withdrawal followed by interferon therapy is an alternative approach for treating chronic hepatitis B virus infection when there has been no therapeutic response to interferon alone. The effectiveness of... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Outcome after Living Donor Liver Transplantation in Patients with Hepatitis C Virus-associated Cirrhosis
-
Park JI, Choi KM, Lee SG, Hwang S, Kim KH, Ahn CS, Moon DB, Chung YH, Lee YS, Suh DJ
- KMID: 1776830
- Korean J Hepatol.
- 2007 Dec;13(4):543-555.
- doi: 10.3350/kjhep.2007.13.4.543
BACKGROUND AND AIMS: Hepatitis C virus (HCV)-associated cirrhosis is an increasingly frequent indication for liver transplantation (LT). However, HCV recurrence is universal and this immediately occurs following LT, which... -
- CITED
-
- Close
- SHARE
-
- Close
- Monitoring antibody titers to recombinant Core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy
-
Park YM, Byun BH, Choi JY, Bae SH, Kim BS, So HS, Ryu WS
- KMID: 648075
- J Korean Med Sci.
- 1999 Apr;14(2):165-170.
- doi: 10.3346/jkms.1999.14.2.165
To evaluate the clinical feasibility of the antibody titer against a chimeric polypeptide (named Core 518), in which a domain of Core and NS3 of hepatitis C virus (HCV) was... -
- CITED
-
- Close
- SHARE
-
- Close
